Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.

作者信息

Tannock Ian F, Pond Gregory R, Booth Christopher M

机构信息

Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

出版信息

JAMA Oncol. 2022 May 1;8(5):679-680. doi: 10.1001/jamaoncol.2021.8206.

DOI:10.1001/jamaoncol.2021.8206

PMID:35266952

Abstract

摘要

相似文献

[1]

Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.

JAMA Oncol. 2022-5-1

[2]

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.

J Clin Oncol. 2024-3-10

[3]

Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.

Eur J Cancer. 2014-9

[4]

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.

Cancer J. 2009

[5]

Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.

Curr Oncol Rep. 2009-1

[6]

Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.

Eur J Cancer. 2014-9

[7]

Progression-free survival in oncology: Caveat emptor!

Basic Clin Pharmacol Toxicol. 2018-12-12

[8]

Inappropriate use of progression-free survival in cancer drug approvals.

BMJ. 2020-3-10

[9]

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.

JAMA Oncol. 2017-7-1

[10]

Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.

Cancer J. 2009

引用本文的文献

[1]

Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized C MRI-A Correlative Study with Clinical Outcomes.

Cancers (Basel). 2025-7-1

[2]

How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes.

Oncologist. 2025-7-4

[3]

Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas.

Pharmacoeconomics. 2025-3-29

[4]

Putting Patients First: Pragmatic Trials in Gynecologic Oncology.

Curr Oncol. 2025-2-27

[5]

Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials.

Transl Lung Cancer Res. 2025-2-28

[6]

A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer.

Biomark Insights. 2025-2-14

[7]

Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward.

EClinicalMedicine. 2024-9-13

[8]

Changes in essential cancer medicines and association with cancer outcomes: an observational study of 158 countries.

BMC Cancer. 2024-12-18

[9]

Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy.

Radiol Med. 2025-2

[10]

Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit.

BJC Rep. 2024-6-24

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献